T1	Participants 518 565	Patients with steroid-dependent Crohn's disease
T2	Participants 926 934	Patients
T3	Participants 1135 1143	patients
T4	Participants 1479 1496	treatment groups.
T5	Participants 1395 1411	placebo patients
T6	Participants 1358 1373	CDP571 patients
